Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline and Celecoxib in Parkinson's Disease
NCT05962957Phase 2Completed
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pentoxifylline and celecoxib in Parkinson's disease (PD) (3 arms). Primary endpoint: Unified Parkinson's Disease Rating Scale Total Score at 6 months. Started Aug 2023; status: completed.
02
Drugs
pentoxifyllinecelecoxib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05962957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962957.